DEVELOPMENT OF ANTI-HUMAN-B BLOOD GROUP MONOCLONAL-ANTIBODIES SUITABLE AS A BLOOD TYPING REAGENT
dc.contributor.author | BECKER, MI | |
dc.contributor.author | JUICA, F | |
dc.contributor.author | JAMETT, A | |
dc.contributor.author | TZICHINOVSKY, S | |
dc.contributor.author | BARROS, S | |
dc.contributor.author | AGUAYO, J | |
dc.contributor.author | DEIOANNES, AE | |
dc.date.accessioned | 2025-01-21T01:35:20Z | |
dc.date.available | 2025-01-21T01:35:20Z | |
dc.date.issued | 1994 | |
dc.description.abstract | An improved procedure for the generation of high-avidity anti-human B blood group monoclonal antibodies (MAbs) was developed. One of them, termed 7A1-2, showed excellent qualities of titer, avidity, and intensity required For use as human B blood typing reagent. Hemagglutination inhibition studies with monosaccharides and oligosaccharides were carried out to determine the specificity of the MAb 7A1-2. These studies indicate that the antibody reacts with the immunodominant region of the antigen which is known to confer the serologic specificity of this blood group. | |
dc.fuente.origen | WOS | |
dc.identifier.issn | 0272-457X | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/97669 | |
dc.identifier.wosid | WOS:A1994PQ89200007 | |
dc.issue.numero | 4 | |
dc.language.iso | en | |
dc.pagina.final | 310 | |
dc.pagina.inicio | 303 | |
dc.revista | Hybridoma | |
dc.rights | acceso restringido | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | DEVELOPMENT OF ANTI-HUMAN-B BLOOD GROUP MONOCLONAL-ANTIBODIES SUITABLE AS A BLOOD TYPING REAGENT | |
dc.type | artículo | |
dc.volumen | 13 | |
sipa.index | WOS | |
sipa.trazabilidad | WOS;2025-01-12 |